Table 2.
Adjusted rate ratios for serious cardiovascular events, associated with ADHD medication use, remote use comparison
Medication status | Person- yrs |
Number Events |
Rate/1,000 person-yrs |
Unadjusted RR |
Adjusted matching variables RRa |
Adjusted RRb |
95% CI |
---|---|---|---|---|---|---|---|
MI | |||||||
Current use | 113,324.2 | 152 | 1.34 | 0.64 | 0.98 | 1.08 | 0.86 – 1.36 |
Amphetamines | 49,080.1 | 59 | 1.20 | 0.57 | 0.99 | 1.12 | 0.83 – 1.52 |
Methylphenidate | 51,232.8 | 77 | 1.50 | 0.71 | 1.00 | 1.10 | 0.83 – 1.45 |
Atomoxetine | 8,424.8 | 11 | 1.31 | 0.62 | 0.99 | 1.06 | 0.57 – 1.96 |
Pemoline | 3,047.3 | 5 | 1.64 | 0.78 | 0.87 | 0.87 | 0.36 – 2.12 |
Multiple | 1,539.1 | 0 | 0.00 | -- | -- | -- | -- |
Indeterminate use | 53,896.7 | 86 | 1.60 | 0.76 | 1.19 | 1.31 | 1.00 – 1.71 |
Former use | 47,858.5 | 65 | 1.36 | 0.64 | 0.92 | 0.96 | 0.71 – 1.28 |
Remote use | 69,792.9 | 147 | 2.11 | 1.00 | 1.00 | 1.00 | reference |
SCDc | |||||||
Current use | 107,525.0 | 32 | 0.30 | 0.41 | 0.79 | 0.82 | 0.52 – 1.29 |
Amphetamines | 46,910.0 | 13 | 0.28 | 0.38 | 0.85 | 0.94 | 0.51 – 1.76 |
Methylphenidate | 47,887.1 | 13 | 0.27 | 0.37 | 0.66 | 0.68 | 0.37 – 1.27 |
Atomoxetine | 8,257.6 | 4 | 0.48 | 0.66 | 1.14 | 1.06 | 0.38 – 2.95 |
Pemoline | 2,995.7 | 2 | 0.67 | 0.91 | 1.11 | 1.10 | 0.27 – 4.56 |
Multiple | 1,474.5 | 0 | 0.00 | -- | -- | -- | -- |
Indeterminate use | 51,814.0 | 14 | 0.27 | 0.37 | 0.70 | 0.74 | 0.41 – 1.35 |
Former use | 46,263.5 | 20 | 0.43 | 0.59 | 0.94 | 0.92 | 0.55 – 1.55 |
Remote use | 68,102.6 | 50 | 0.73 | 1.00 | 1.00 | 1.00 | reference |
Stroked | |||||||
Current use | 111,935.5 | 63 | 0.56 | 0.58 | 0.90 | 0.93 | 0.65 – 1.31 |
Amphetamines | 48,672.9 | 19 | 0.39 | 0.40 | 0.70 | 0.77 | 0.46 – 1.29 |
Methylphenidate | 50,332.3 | 39 | 0.77 | 0.80 | 1.15 | 1.15 | 0.77 – 1.72 |
Atomoxetine | 8,371.1 | 3 | 0.36 | 0.37 | 0.55 | 0.54 | 0.17 – 1.71 |
Pemoline | 3,030.1 | 2 | 0.66 | 0.68 | 0.74 | 0.72 | 0.18 – 2.96 |
Multiple | 1,529.2 | 0 | 0.00 | -- | -- | -- | -- |
Indeterminate use | 53,327.8 | 31 | 0.58 | 0.60 | 0.96 | 1.01 | 0.65 – 1.54 |
Former use | 47,333.0 | 39 | 0.82 | 0.85 | 1.24 | 1.23 | 0.83 – 1.83 |
Remote use | 69,202.3 | 67 | 0.97 | 1.00 | 1.00 | 1.00 | reference |
MI, SCD or strokec,d | |||||||
Current use | 107,322.4 | 234 | 2.18 | 0.61 | 0.96 | 1.03 | 0.86 – 1.24 |
Amphetamines | 46,826.5 | 88 | 1.88 | 0.52 | 0.93 | 1.05 | 0.82 – 1.34 |
Methylphenidate | 47,792.3 | 120 | 2.51 | 0.70 | 1.01 | 1.07 | 0.86 – 1.34 |
Atomoxetine | 8,248.2 | 17 | 2.06 | 0.57 | 0.90 | 0.92 | 0.56 – 1.50 |
Pemoline | 2,985.2 | 9 | 3.01 | 0.84 | 0.95 | 0.93 | 0.48 – 1.82 |
Multiple | 1,470.1 | 0 | 0.00 | -- | -- | -- | -- |
Indeterminate use | 51,709.6 | 125 | 2.42 | 0.67 | 1.09 | 1.17 | 0.94 – 1.45 |
Former use | 46,120.8 | 121 | 2.62 | 0.73 | 1.06 | 1.07 | 0.86 – 1.33 |
Remote use | 67,489.0 | 243 | 3.60 | 1.00 | 1.00 | 1.00 | reference |
Abbreviations: MI, myocardial infarction; SCD, sudden cardiac death; RR, rate ratio; CI, confidence interval; CRS, cardiovascular risk score; KP, Kaiser Permanente
Adjusted for site, age, sex, and calendar year (ie, matching variables).
Adjusted for site, age, sex, calendar year, and CRS (some variables within score are time-varying).
Analyses excluded the three HMORN sites (Fallon Community, KP Georgia, KP Northwest) that did not provide data on SCD endpoints.
Analyses excluded the two HMORN sites (Fallon Community, KP Georgia) that did not provide data on stroke endpoints.